BI 6015 |
| Katalog-Nr.GC13231 |
BI 6015 ist ein Antagonist des Hepatozyten-Kernfaktors 4α (HNF4α), der die Expression bekannter HNF4α-Zielgene hemmen kann.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 93987-29-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BI 6015 is an antagonist of hepatocyte nuclear factor 4α [1].
Hepatocyte nuclear factor 4α (HNF4α) is a nuclear receptor and regulates gene expression in enterocytes, hepatocytes and pancreatic β cells [1].
BI 6015 is a HNF4α antagonist. BI6015 inhibited the insulin promoter. In T6PNE cells, BI6015 reduced the expression of endogenous insulin by 50-fold. In MIN6 and HepG2 cells, BI6015 inhibited the expression of HNF4α. Also, BI6015 changed HNF4α protease sensitivity [1]. In T6PNE cells, BI 6015 reduced the levels of longer chain acylcarnitines (C18, C18:1, C16, and C14) and increased acetylcarnitine, which suggested that BI 6015 increased fatty acid oxidation. In the human hepatoma cell line Hep3B, BI 6015 exhibited cytotoxic activity [1].
In mice, BI6015 (30 mg/kg) induced a loss of HNF4α protein in the liver, but not in the kidney and intestine. Also, BI6015 caused fat accumulation and steatosis and vesicular changes in a dose-dependent way [1].
Reference:
[1]. Kiselyuk A, Lee SH, Farber-Katz S, et al. HNF4a Antagonists Discovered by a High-Throughput Screen for Modulators of the Human Insulin Promoter. Chem Biol, 2012, 19(7): 806-818.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *